COVID-19 – Dexamethasone
The initial clinical trial results from the UK regarding the use of dexamethasone on treating those who are critically ill with COVID-19 are very promising.
Dexamethasone is a low-cost steroid that has been in use since the 1960’s to treat a range of conditions including arthritis, severe allergies and certain cancers. It works by dampening the body’s immune response and preventing a severe immune reaction, which researchers believe is responsible for causing some COVID patients to have multiple organ failure and increased mortality.
According to preliminary findings shared with World Health Organisation (WHO) patients on ventilators were shown to have mortality rates reduced by around one third, and for patients requiring only oxygen, mortality was cut by approximately one fifth.
WHO note the benefit has only been seen in patients seriously ill with COVID-19, and has not been observed in patients with milder disease.
HM Government of Gibraltar are pleased to report (see press release here) that the GHA already holds considerable stocks of a dexamethasone, and at a time where Gibraltar can currently boast zero active cases of COVID-19.
It is important to remember that our aim is to reduce the risk of any potentially critical cases by adhering to the traditional public health measures, such as physical distancing and contact tracing.